title: Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
abstract: OBJECTIVE
  Some authors have claimed a significant impact of β-blocking agents on outcome in epithelial ovarian cancer (EOC). This study investigated the impact of concurrent medication with selective beta blockers (SBB) in patients undergoing primary treatment for EOC.
  
  
  METHODS
  The study included all consecutive patients with primary EOC treated in two tertiary gynecological-oncologic units between 1999 and 2014. Medication was retrospectively analyzed by chart review.
  
  
  RESULTS
  The study cohort comprised 801 patients, of whom 141 (17.6%) had received SBB. Median age of patients without SBB medication was 56years (range: 19-90years) and 64years (range: 41-84years) in patients taking SBB (p<0.001). The main prognostic factor FIGO stage did not differ between both cohorts. 63.8% of patients taking SBB underwent complete tumor resection compared to 74.2% of patients without SBB (p=0.012). Patients without SBB experienced less severe post-operative complications according to the Clavien-Dindo classification (18.8% vs 29.0%; p=0.003). Between the both groups without and with SBB intake, PFS and OS did not differ significantly (PFS: 27months and 24months, p=0.40; OS: 56months and 44, p=0.15). Multivariate analyses did not yield any association between SBB intake and prognosis but confirmed well-known prognostic factors.
  
  
  CONCLUSIONS
  Intake of selective β-blockers did not influence the prognosis of patients with EOC.
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany. Electronic address: florian.heitz@gmx.net.
authors.forename: Florian
authors.initials: F
authors.lastname: Heitz
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Hengsbach
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Traut
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Beyhan
authors.initials: B
authors.lastname: Ataseven
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Schneider
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Sonia
authors.initials: S
authors.lastname: Prader
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Kurzeder
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Mareike
authors.initials: M
authors.lastname: Sporkmann
authors.affiliation: Department of Gynecology and Gynecologic Oncology; Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: du Bois
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000401:mortality* / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D011183:Postoperative Complications / Q000453:epidemiology*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
keywords: Beta blockers; Epithelial ovarian cancer; Survival